Hepatitis B, Chronic Clinical Trial
Official title:
An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Participants With Chronic HBV Infection Who Are Non-Cirrhotic, Hepatitis B e Antigen-negative, and Virally Suppressed
IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of chronic hepatitis B virus (HBV) infection (CHB). This is the first in-human study of IMC-I109V in persons with CHB.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | December 15, 2024 |
Est. primary completion date | September 10, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria Parts 1 and 2: - =18 to 65 years old at time of informed consent - HLA-A*02:01 positive - Documented evidence of CHB based on one of the following: a. Positive HBsAg and HBV DNA at least 6 months prior to the Screening visit; OR b. Historical liver biopsy consistent with CHB infection. - Have been receiving entecavir and/or tenofovir (including tenofovir alafenamide) for =12months prior to screening and are willing to continue. - HBV DNA negative at screening - No history of liver cirrhosis AND prior assessment of fibrosis demonstrating non-cirrhotic status at screening - Participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 3 months after the final dose of the study intervention or longer if required by local regulations Part 3: - =18 years old at time of informed consent - HLA-A*02:01 positive - ECOG =1 - Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology / cytology, or clinically by American Association for the Study of Liver Diseases criteria - Failed or intolerant of =1 systemic therapy - At least one measurable lesion (per RECIST 1.1) which is either not previously treated or, if treated, has clearly progressed prior to enrollment - Documented evidence of CHB based on one of the following: a. Positive HBsAg and HBV DNA at least 6 months prior to the Screening visit; OR b. Historical liver biopsy consistent with CHB infection - Life expectancy >3 months from time of enrolment - Have compensated cirrhosis with a Child-Pugh score = 7 (A or B7) - On entecavir and/or tenofovir (disoproxil fumarate or alafenamide) with HBV DNA <100IU/ml at screening; willingness to continue for at least 6 months after the last dose of study drug - Quantitative HBV surface antigen = 5,000 IU/mL at screening - Participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 3 months after the final dose of the study intervention or longer if required by local regulations Exclusion Criteria: Parts 1 and 2: - Pregnant or lactating persons - Known co-infection with any of the following: HIV, Hepatitis C virus, OR Hepatitis D virus - Changes in HBeAg status within 3 months prior to the screening visit - Known HBV genotype A - Gilbert's syndrome - Any known pre-existing medical or psychiatric condition that could interfere with the participant's ability to provide informed consent or participate in study conduct, or that may confound study findings including, but not limited to: Immunologically-mediated disease, e.g. inflammatory bowel disease (Crohn's disease, ulcerative colitis), rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, scleroderma, or sarcoidosis within 5 years of the screening visit. - Current or history of any clinically significant cardiac abnormalities/dysfunction, e.g. congestive heart failure, myocardial infarction =6 months prior to the screening visit, pulmonary hypertension, complex congenital heart disease, significant arrhythmia, or active cardiac ischemia. - Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding esophageal varices, hepatorenal syndrome, or hepatic encephalopathy. - Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia - Evidence of active or suspected malignancy, or a history of malignancy =3 years prior to the screening visit (except adequately treated carcinoma in situ, basal cell carcinoma of the skin, or stage 0 HCC that has been treated). NOTE: Participants under evaluation for malignancy are not eligible - Receiving or planning to receive systemic immunosuppressive medications during the study or = 2 months prior to Day1, including but not limited to prednisone >10 mg/day (or equivalent), methotrexate, cyclosporine, or interferon. NOTE: Local steroid therapy is allowed (eg, inhaled, otic, ophthalmic, or intra-articular medications) - Use of any live vaccines against infectious diseases within 4 weeks of the first planned administration of study intervention or use of any non-live vaccines against infectious diseases within 2 weeks of the first planned administration of study intervention. - Treatment with any investigational drug or enrollment in any other clinical study = 3 months prior to Day1, or at any time during participation in the study. - Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine =12 months prior to the screening visit, except for those participants monitored in an opioid substitution maintenance program. Part 3: - Pregnant or lactating persons - Untreated or symptomatic CNS metastases - Significant ongoing toxicity from prior anticancer treatment - - Ascites requiring recurrent paracentesis - Inadequate washout from prior anticancer therapy - Prior cellular therapy for HBV-associated HCC - Known HBV genotype A - Decompensated liver disease - Surgical intervention or local / loco-regional therapy for HBV HCC within 28 days of planned first dose of study treatment - Active hepatitis C virus (HCV) infection - Untreated HIV infection - Significant secondary malignancy - Clinically significant lung, heart, or autoimmune disease - Ongoing requirement for immunosuppressive treatment - Prior solid organ or bone marrow transplant - Hypersensitivity to study drug or excipients, or pre-medications - Systemic antibiotics, vaccines or major surgery within 2-4 weeks prior to the first dose of study intervention - Out-of-range laboratory values, including ALT or AST > 3x upper limit of normal (ULN), total bilirubin and direct bilirubin > 1.5x ULN, Albumin = 28 g/L, International normalized ratio (INR) > 1.3 |
Country | Name | City | State |
---|---|---|---|
Australia | St. Vincent's Hospital | Fitzroy | |
Australia | The Alfred Centre | Melbourne | |
Denmark | Aarhus University | Aarhus | |
Hong Kong | Queen Mary Hospital | Hong Kong | |
Korea, Republic of | Pusan National University Hospital | Busan | |
Romania | ARENSIA Exploratory Medicine Research Clinic | Bucharest | |
Spain | Hospital Universitari Vall d'Hebron de Barcelona | Barcelona | |
Spain | Hospital Ramón and Cajal | Madrid | |
Taiwan | Kaohsiung Medical University Chung-Ho | Kaohsiung City | |
Taiwan | Taipei Veterans General Hospital | Taipei city | |
United Kingdom | Chelsea and Westminster Hospital, Research and Development, Clinical Trials Facility | London | |
United Kingdom | Guy's Hospital, Dept. of Infectious Disease | London | |
United Kingdom | Nottingham University Hospitals NHS Trust Biomedical Research Centre | Nottingham | |
United States | University Hospitals Cleveland Medical Center Case Western Reserve | Cleveland | Ohio |
United States | University of Southern California Keck School of Medicine | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Immunocore Ltd |
United States, Australia, Denmark, Hong Kong, Korea, Republic of, Romania, Spain, Taiwan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Parts 1, 2, and 3: Incidence and treatment-emergent adverse events (TEAEs) | Up to 30 days after the last infusion of study treatment | ||
Primary | Parts 1, 2, and 3: Incidence of serious adverse events (SAEs) | Up to 30 days after the last infusion of study treatment | ||
Primary | Parts 1, 2, and 3: Incidence of adverse events (AEs) leading to treatment discontinuation | Up to 30 days after the last infusion of study treatment | ||
Primary | Parts 1, 2, and 3: Incidence of dose-limiting toxicities (DLTs) | Up to 30 days after the last infusion of study treatment | ||
Primary | Parts 1, 2, and 3: Changes in Vital Signs | Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) vital sign abnormalities. | Up to 30 days after the last infusion of study treatment | |
Primary | Parts 1, 2, and 3: Changes in electrocardiogram | QTcF interval absolute values and changes from baseline. | Up to 30 days after the last infusion of study treatment | |
Primary | Parts 1, 2, and 3: Change in safety laboratory parameters | Number of participants with, and rate of, Grade 1, Grade 2, Grade 3, and Grade 4 (as applicable per NCI CTCAE v5.0) laboratory abnormalities. | Up to 30 days after the last infusion of study treatment | |
Secondary | Parts 1, 2, and 3: Maximum drug concentration (Cmax) | At designated timepoints up to 162 days post-dose | ||
Secondary | Parts 1, 2, and 3: Area under the plasma concentration versus time curve (AUC) | At designated timepoints up to 162 days post-dose | ||
Secondary | Parts 1, 2, and 3: The time to reach maximum drug concentration (Tmax) | At designated timepoints up to 162 days post-dose | ||
Secondary | Parts 1, 2, and 3: The elimination half-life (t1/2) | At designated timepoints up to 162 days post-dose | ||
Secondary | Parts 1, 2, and 3: Incidence of anti-IMC-109V antibody formations | At designated timepoints up to 162 days post-dose | ||
Secondary | Parts 1, 2, and 3: Antiviral Effects: HBsAg change from baseline | Up to 280 days post-dose | ||
Secondary | Parts 1, 2, and 3: Antiviral Effects: HBcrAg change from baseline | Up to 280 days post-dose | ||
Secondary | Parts 1, 2, and 3: Antiviral Effects: HBV RNA change from baseline | Up to 280 days post-dose | ||
Secondary | Parts 1, 2, and 3: Antiviral Effects: HBsAb change from baseline | Up to 280 days post-dose | ||
Secondary | Part 3 only: Objective response rate (ORR) as determined by RECIST v1.1 as assessed by the Investigator | Up to ~52 months | ||
Secondary | Part 3 only: Overall survival (OS) as determined by RECIST v1.1 as assessed by the Investigator | Up to ~52 months | ||
Secondary | Part 3 only: Progression-free survival (PFS) as determined by RECIST v1.1 as assessed by the Investigator | Up to ~52 months | ||
Secondary | Part 3 only: Duration of response (DOR) as determined by RECIST v1.1 as assessed by the Investigator | Up to ~52 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03272009 -
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
|
Phase 1 | |
Recruiting |
NCT01456312 -
HBsAg Related Response Guided Therapy
|
Phase 4 | |
Terminated |
NCT01886300 -
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam
|
N/A | |
Completed |
NCT00962975 -
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies
|
Phase 1 | |
Completed |
NCT01023230 -
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
|
Phase 1 | |
Completed |
NCT00536263 -
PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)
|
Phase 3 | |
Terminated |
NCT00460850 -
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
|
Phase 4 | |
Completed |
NCT03681132 -
The Norwegian Nucleoside Analogue Stop Study
|
Phase 4 | |
Active, not recruiting |
NCT05473806 -
Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
|
Phase 4 | |
Withdrawn |
NCT01179594 -
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
|
Phase 4 | |
Recruiting |
NCT05057065 -
A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
|
||
Completed |
NCT04439539 -
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
|
Phase 2 | |
Withdrawn |
NCT03125213 -
A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects
|
Phase 2 | |
Active, not recruiting |
NCT04782375 -
Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B
|
Phase 4 | |
Withdrawn |
NCT05550519 -
A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment
|
Early Phase 1 | |
Completed |
NCT02693652 -
A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT04160897 -
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
|
||
Active, not recruiting |
NCT02588937 -
Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients
|
Phase 4 | |
Completed |
NCT02612506 -
Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT02327416 -
A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)
|
Phase 3 |